Collaborative and Other Relationships - OCREVUS (Details) - USD ($) $ in Millions |
1 Months Ended | 3 Months Ended |
|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2024 |
|
| OCREVUS | ||
| Collaborative arrangements and non-collaborative arrangement transactions | ||
| Royalty operating profit threshold for highest royalty rate percentage | $ 900.0 | |
| Reduction in royalty rate | 50.00% | |
| Collaboration agreement term | 11 years | |
| OCREVUS | Foreign Tax Authority | ||
| Collaborative arrangements and non-collaborative arrangement transactions | ||
| Royalty percentage to be received | 3.00% | |
| OCREVUS | Minimum | ||
| Collaborative arrangements and non-collaborative arrangement transactions | ||
| Royalty percentage to be received | 13.50% | |
| OCREVUS | Maximum | ||
| Collaborative arrangements and non-collaborative arrangement transactions | ||
| Royalty percentage to be received | 24.00% | |
| Mosunetuzumab | ||
| Collaborative arrangements and non-collaborative arrangement transactions | ||
| Percentage of future development costs | 30.00% |